Pacira BioSciences, Inc. PCRX ZILRETTA — Total net product sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s zilretta — total net product sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s ZILRETTA — total net product sales?
- Pacira BioSciences, Inc. (PCRX) reported ZILRETTA — total net product sales of $26.77M in Q1 2026.
- How has Pacira BioSciences, Inc.'s ZILRETTA — total net product sales changed year-over-year?
- Pacira BioSciences, Inc.'s ZILRETTA — total net product sales increased by 14.7% year-over-year, from $23.34M to $26.77M.
- What is the long-term trend for Pacira BioSciences, Inc.'s ZILRETTA — total net product sales?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s ZILRETTA — total net product sales has grown at a 74.1% compound annual growth rate (CAGR), from $12.68M to $116.63M.
- What does ZILRETTA — total net product sales mean?
- This metric represents the total revenue generated from the sale of a specific pharmaceutical product after accounting for returns, rebates, and other sales deductions. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the company's overall top-line growth. Monitoring this figure helps investors assess the product's lifecycle stage and its ability to sustain competitive positioning within its therapeutic category.